Media stories about Vitamin Shoppe (NYSE:VSI) have been trending somewhat positive on Saturday, AlphaOne Sentiment Analysis reports. The research group, a service of Accern, identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vitamin Shoppe earned a news impact score of 0.03 on AlphaOne’s scale. AlphaOne also assigned headlines about the specialty retailer an impact score of 95 out of 100, indicating that recent press coverage is extremely likely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted AlphaOne Sentiment Analysis’s rankings:
- Gabelli Weighs in on Vitamin Shoppe Inc’s FY2017 Earnings (VSI) (americanbankingnews.com)
- Vitamin Shoppe (NYSE:VSI) reports 1Q17 Profit Down 45%; Misses Street View (gizpress.com)
- Vitamin Shoppe Inc (VSI) Given “Equal Weight” Rating at Barclays PLC (americanbankingnews.com)
- Vitamin Shoppe Inc (VSI) Upgraded at Morgan Stanley (americanbankingnews.com)
- Vitamin Shoppe Inc (VSI) Lowered to Hold at Gabelli (americanbankingnews.com)
Shares of Vitamin Shoppe (NYSE:VSI) traded up 1.71% during midday trading on Friday, reaching $11.90. The company’s stock had a trading volume of 392,712 shares. The company has a market cap of $275.64 million, a PE ratio of 15.32 and a beta of 0.59. Vitamin Shoppe has a 12 month low of $11.50 and a 12 month high of $32.31. The company’s 50-day moving average price is $17.70 and its 200-day moving average price is $21.50.
Vitamin Shoppe (NYSE:VSI) last issued its quarterly earnings data on Wednesday, May 10th. The specialty retailer reported $0.37 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.58 by $0.21. The firm had revenue of $316.90 million for the quarter, compared to analysts’ expectations of $325.71 million. Vitamin Shoppe had a net margin of 3.34% and a return on equity of 11.52%. The company’s revenue for the quarter was down 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.67 EPS. On average, equities analysts anticipate that Vitamin Shoppe will post $1.56 EPS for the current fiscal year.
Several equities research analysts have issued reports on VSI shares. Zacks Investment Research lowered Vitamin Shoppe from a “hold” rating to a “sell” rating in a research note on Wednesday, May 3rd. Goldman Sachs Group Inc dropped their price target on Vitamin Shoppe from $22.00 to $19.00 and set a “sell” rating for the company in a research note on Thursday, March 23rd. Barclays PLC reaffirmed an “equal weight” rating and set a $13.00 price target (down previously from $24.00) on shares of Vitamin Shoppe in a research note on Sunday, May 14th. Gabelli lowered Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Finally, Morgan Stanley raised Vitamin Shoppe from an “underweight” rating to an “equal weight” rating and set a $14.00 price target for the company in a research note on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $24.00.
In related news, CAO Dan Lamadrid sold 5,432 shares of Vitamin Shoppe stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $22.36, for a total value of $121,459.52. Following the completion of the transaction, the chief accounting officer now owns 16,817 shares in the company, valued at $376,028.12. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard L. Markee sold 100,000 shares of Vitamin Shoppe stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $22.24, for a total value of $2,224,000.00. Following the completion of the transaction, the director now owns 160,990 shares of the company’s stock, valued at approximately $3,580,417.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 108,161 shares of company stock valued at $2,398,429. Company insiders own 1.29% of the company’s stock.
About Vitamin Shoppe
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.